We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.